SPAG6 and acute myeloid leukemia: Detection of minimal residual disease (MRD) is essential for the diagnosis and management of acute myeloid leukemia (AML), and SPAG6 has been identified as a prospective biomarker for detecting MRD in pediatric AML patients [32].